• Coherus Oncology entered a clinical collaboration with Zumutor Biologics to test ZM008 with LOQTORZI (toripalimab-tpzi) in Phase 1.
• Zumutor will sponsor the U.S. study; Coherus will supply LOQTORZI under a clinical trial collaboration and supply agreement.
• Trial NCT06451497 targets solid tumors; enrollment up to 45 patients across dose-escalation and expansion cohorts.
• Partners retained commercial rights to their respective drugs for monotherapy use or in combinations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606231400PRIMZONEFULLFEED9751311) on June 23, 2026, and is solely responsible for the information contained therein.